
Sign up to save your podcasts
Or


The Indian Council for Medical Research said on May 26 that no major side-effects of Hydroxychloroquine have been found in studies in India and its use should be continued in preventive treatment for COVID-19. This all comes in the backdrop of the World Health Organization (WHO) suspending the testing of the drug in COVID-19 patients temporarily in its global study following safety concerns. Why is India pushing ahead with the drug and what are the kinds of trials it is running to test its efficacy?
Guests: Jacob Koshy, Deputy Science Editor, The Hindu.
Find the In Focus podcast on Spotify, Apple Podcasts and Stitcher. Search for In Focus by The Hindu.
Learn more about your ad choices. Visit megaphone.fm/adchoices
By The Hindu4.5
3737 ratings
The Indian Council for Medical Research said on May 26 that no major side-effects of Hydroxychloroquine have been found in studies in India and its use should be continued in preventive treatment for COVID-19. This all comes in the backdrop of the World Health Organization (WHO) suspending the testing of the drug in COVID-19 patients temporarily in its global study following safety concerns. Why is India pushing ahead with the drug and what are the kinds of trials it is running to test its efficacy?
Guests: Jacob Koshy, Deputy Science Editor, The Hindu.
Find the In Focus podcast on Spotify, Apple Podcasts and Stitcher. Search for In Focus by The Hindu.
Learn more about your ad choices. Visit megaphone.fm/adchoices

156 Listeners

11 Listeners

56 Listeners

64 Listeners

87 Listeners

102 Listeners

41 Listeners

23 Listeners

11 Listeners

4 Listeners

15 Listeners

9 Listeners

9 Listeners

95 Listeners

13 Listeners